WO2007084661A3 - Therapy-enhancing glucan - Google Patents
Therapy-enhancing glucan Download PDFInfo
- Publication number
- WO2007084661A3 WO2007084661A3 PCT/US2007/001427 US2007001427W WO2007084661A3 WO 2007084661 A3 WO2007084661 A3 WO 2007084661A3 US 2007001427 W US2007001427 W US 2007001427W WO 2007084661 A3 WO2007084661 A3 WO 2007084661A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- glucan
- therapy
- antitumor
- mammal
- Prior art date
Links
- 229920001503 Glucan Polymers 0.000 title abstract 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 2
- 238000009566 cancer vaccine Methods 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 abstract 1
- 229920002498 Beta-glucan Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008551413A JP2009528267A (en) | 2006-01-17 | 2007-01-17 | Glucan to enhance treatment |
PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
US12/161,285 US8323644B2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
EP07718218A EP1984004A4 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
CA002637205A CA2637205A1 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
AU2008207369A AU2008207369B2 (en) | 2006-01-17 | 2008-08-18 | Immune response enhancing glucans |
US12/212,352 US20090053221A1 (en) | 2006-01-17 | 2008-09-17 | Immune response enhancing glucan |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/334,763 | 2006-01-17 | ||
US11/334,763 US7906492B2 (en) | 2001-01-16 | 2006-01-17 | Therapy-enhancing glucan |
PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/334,763 Continuation-In-Part US7906492B2 (en) | 2001-01-16 | 2006-01-17 | Therapy-enhancing glucan |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008207369A Division AU2008207369B2 (en) | 2006-01-17 | 2008-08-18 | Immune response enhancing glucans |
US12/212,352 Continuation-In-Part US20090053221A1 (en) | 2006-01-17 | 2008-09-17 | Immune response enhancing glucan |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007084661A2 WO2007084661A2 (en) | 2007-07-26 |
WO2007084661A3 true WO2007084661A3 (en) | 2007-11-08 |
WO2007084661B1 WO2007084661B1 (en) | 2008-01-10 |
Family
ID=40382391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/001427 WO2007084661A2 (en) | 2006-01-17 | 2007-01-17 | Therapy-enhancing glucan |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1984004A4 (en) |
JP (1) | JP2009528267A (en) |
AU (1) | AU2008207369B2 (en) |
WO (1) | WO2007084661A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7906492B2 (en) | 2001-01-16 | 2011-03-15 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
US7507724B2 (en) | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
JP5153188B2 (en) * | 2007-03-30 | 2013-02-27 | 小林製薬株式会社 | Th1 / Th2 balance improver |
WO2009063221A2 (en) * | 2007-11-13 | 2009-05-22 | Biotec Pharmacon Asa | Methods of treating or preventing inflammatory diseases of the intestinal tract |
JP5242855B2 (en) * | 2010-07-29 | 2013-07-24 | 国立大学法人北海道大学 | Immune adjuvant |
WO2012105219A1 (en) * | 2011-01-31 | 2012-08-09 | オリンパス株式会社 | Antibody therapy effect-enhancing drug |
CN104812396B (en) * | 2012-04-30 | 2019-07-09 | 生物治疗公司 | Beta glucan immunotherapy method |
EP2832360A1 (en) | 2013-07-30 | 2015-02-04 | Fresenius Kabi Deutschland GmbH | Polysaccharide for use in preventing metastasis formation and/or relapse |
CN106687122B (en) * | 2014-07-10 | 2020-11-10 | 百奥赛诺公司 | Combination of beta-glucan and an anti-cancer agent affecting the tumor microenvironment |
US11815435B2 (en) | 2017-02-24 | 2023-11-14 | Hibercell, Inc. | Beta glucan immunopharmacodynamics |
WO2019178236A1 (en) * | 2018-03-13 | 2019-09-19 | Biothera Pharmaceuticals, Inc. | Beta glucan and cd40 agonist combination immunotherapy |
CA3097980A1 (en) * | 2018-04-24 | 2019-10-31 | Memorial Sloan Kettering Cancer Center | Methods of enhancing immunogenicity of poorly immunogenic antigen-specific vaccines using oral yeast beta-glucans |
WO2020061203A1 (en) * | 2018-09-21 | 2020-03-26 | Nantcell, Inc. | Methods and compositions for modulating myeloid-derived suppressor cells |
JP7048102B2 (en) | 2019-05-23 | 2022-04-05 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Application of nucleic acid polysaccharide complex with immunostimulatory activity as an antitumor drug |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130127A (en) * | 1985-03-11 | 1992-07-14 | The Wistar Institute | Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies |
US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US5726023A (en) * | 1993-03-17 | 1998-03-10 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
US5849720A (en) * | 1989-09-08 | 1998-12-15 | Alpha-Beta Technology, Inc. | Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans |
US20060009419A1 (en) * | 2002-09-04 | 2006-01-12 | Ross Gordon D | Therapy-enhancing glucan |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622939A (en) * | 1992-08-21 | 1997-04-22 | Alpha-Beta Technology, Inc. | Glucan preparation |
EP0640348A1 (en) * | 1993-07-26 | 1995-03-01 | Akzo Nobel N.V. | Oil-based and water-based adjuvant mixture |
NO300692B1 (en) * | 1994-04-29 | 1997-07-07 | Biotec Mackzymal As | Solubilized branched β-1,3-glucan and its use, as well as the use of unsolubilized branched β-1,3-glucan |
JP2000516911A (en) * | 1996-03-28 | 2000-12-19 | ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ | Opsonin-enhanced cells and methods of modulating the immune response to antigens |
JP2004507446A (en) * | 2000-02-04 | 2004-03-11 | トーマス・ジェファーソン・ユニバーシティ | Immunotherapy of low-dose haptenized tumor cells and tumor cell extracts |
CA2434938C (en) * | 2001-01-16 | 2012-02-28 | Sloan-Kettering Institute For Cancer Research | Compositions of glucan and a monoclonal antibody which exhibit an enhancement of the anti tumor activity of the antibody |
US7507724B2 (en) * | 2001-01-16 | 2009-03-24 | Sloan-Kettering Institute For Cancer Research | Therapy-enhancing glucan |
GB0211118D0 (en) * | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
US20070059310A1 (en) * | 2005-05-03 | 2007-03-15 | Karel Steven J | Therapeutic combination compositions and methods of using same |
-
2007
- 2007-01-17 EP EP07718218A patent/EP1984004A4/en not_active Withdrawn
- 2007-01-17 JP JP2008551413A patent/JP2009528267A/en active Pending
- 2007-01-17 WO PCT/US2007/001427 patent/WO2007084661A2/en active Application Filing
-
2008
- 2008-08-18 AU AU2008207369A patent/AU2008207369B2/en not_active Ceased
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5130127A (en) * | 1985-03-11 | 1992-07-14 | The Wistar Institute | Human tumor therapy using beta (1-3) glucanlentinan and anti-tumor antibodies |
US5849720A (en) * | 1989-09-08 | 1998-12-15 | Alpha-Beta Technology, Inc. | Enhancement of non-specific immune defenses by administration of underivatized, aqueous soluble glucans |
US5726023A (en) * | 1993-03-17 | 1998-03-10 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated |
US5696079A (en) * | 1993-05-19 | 1997-12-09 | The United States Of America As Represented By The Department Of Health And Human Services | Immunologic enhancement with intermittent interleukin-2 therapy |
US20060009419A1 (en) * | 2002-09-04 | 2006-01-12 | Ross Gordon D | Therapy-enhancing glucan |
Non-Patent Citations (5)
Title |
---|
HELLSTOM ET AL.: "Antitumor effects of L6, an IgG2 antibody that reacts with most human carcinomas", PROC. NATL. ACAD. SCI. USA, vol. 83, September 1986 (1986-09-01), pages 7059 - 7063, XP000939048 * |
HERRERA ET AL.: "Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro", LEUKEMIA, vol. 14, no. 5, 2000, pages 853 - 858, XP008060428 * |
MENDELSOHN J.: "Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy", CLINICAL CANCER RESEARCH, vol. 3, 1997, pages 2703 - 2707, XP002938234 * |
RAI ET AL.: "Monoclonal antibodies in chronic lymphocytic leukemia", REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY, vol. 4, no. 2, 2000, pages 134 - 144, XP008128870 * |
YAN ET AL.: "B-Glucan, a "specific" biologic response modifier that uses antibodies to target tumor for cytotoxic recognition by Leukocyte complement receptor type 3 (CD11B/CD18)", THE JOURNAL OF IMMUNOLOGY, vol. 163, 1999, pages 3045 - 3052, XP008128976 * |
Also Published As
Publication number | Publication date |
---|---|
AU2008207369B2 (en) | 2009-12-17 |
AU2008207369A1 (en) | 2008-09-11 |
WO2007084661A2 (en) | 2007-07-26 |
JP2009528267A (en) | 2009-08-06 |
WO2007084661B1 (en) | 2008-01-10 |
EP1984004A2 (en) | 2008-10-29 |
EP1984004A4 (en) | 2010-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007084661A3 (en) | Therapy-enhancing glucan | |
WO2007100905A3 (en) | Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation | |
WO2011157741A3 (en) | Human antibody drug conjugates against tissue factor | |
WO2007112193A3 (en) | Camptothecin-binding moiety conjugates | |
EP2476704A3 (en) | Humanized monoclonal antibodies to heptocyte growth factor | |
WO2006093784A3 (en) | Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents | |
WO2009100194A3 (en) | Camptothecin-binding moiety conjugates | |
EP4279140A3 (en) | Human antibodies against tissue factor | |
WO2007150077A8 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2008039218A3 (en) | Inhibitors of bruton's tyrosine kinase | |
WO2006113909A3 (en) | Humanized anti-cd70 binding agents and uses thereof | |
WO2009052411A3 (en) | Methods for treatment of thiol-containing compound deficient conditions | |
WO2009064460A3 (en) | Gastrointestinal delivery systems | |
WO2008116195A3 (en) | Compositions comprising an sglt2 ingibitor for treating obesity | |
WO2008036206A3 (en) | Copolymer-bioceramic composite implantable medical devices | |
WO2008083174A3 (en) | Compositions and methods for the treatment of infections and tumors | |
WO2006066074A3 (en) | Lung-targeted drugs | |
WO2007107305A3 (en) | Treatment of triple receptor negative breast cancer | |
WO2007135546A3 (en) | TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES | |
WO2006095029A3 (en) | Di-polymer protein conjugates and processes for their preparation | |
WO2006050155A3 (en) | Cancer therapeutic compositions | |
EP2952210A3 (en) | Compositions comprising saccharide binding moieties and methods for targeted therapy | |
WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer | |
WO2008066784A3 (en) | Expression of foxp3 by cancer cells | |
WO2007098106A3 (en) | Respiratory tract delivery of interferon-tau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2637205 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008551413 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12161285 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1729/MUMNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007718218 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780007540.0 Country of ref document: CN |